5,231 results match your criteria thrombosis arrhythmias


Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews.

Eur Heart J Qual Care Clin Outcomes 2021 Jun 9. Epub 2021 Jun 9.

Liverpool Centre for Cardiovascular Science, University of Liverpool & Liverpool Heart and Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.

Aims: To consolidate evidence to determine (i) the association between cardiovascular risk factors and health outcomes with coronavirus 2019 (COVID-19); and (ii) the impact of COVID-19 on cardiovascular health.

Methods And Results: An umbrella review of systematic reviews was conducted. Fourteen medical databases and pre-print servers were searched from 1 January 2020 to 5 November 2020. Read More

View Article and Full-Text PDF

Brady-arrhythmias in patients with atrial fibrillation and heart failure of reduced ejection fraction: is his-bundle pacing superior to biventricular pacing༟.

Pacing Clin Electrophysiol 2021 Jun 3. Epub 2021 Jun 3.

All authors from Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.

Objective: To investigate the efficacy and safety of His-bundle pacing (HBP) compared with the traditional biventricular pacing (BVP) on patients with brady-arrhythmias, who suffer from permanent atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF).

Methods: All patients with brady-arrhythmias, permanent AF and HFrEF were continuously enrolled from January 2017 to July 2019 and followed up for at least 12 months. The differences in QRS duration (QRSd), New York Heart Association (NYHA) classification, left ventricular ejection fraction (LVEF), tricuspid regurgitation grade, mitral regurgitation grade, left ventricular end-diastolic diameter (LVEDD) and left atrial size were compared. Read More

View Article and Full-Text PDF

Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?

Medicina (Kaunas) 2021 May 31;57(6). Epub 2021 May 31.

Department of Internal Diseases "Prof. St. Kirkovich", Medical University of Sofia, 1431 Sofia, Bulgaria.

Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. An open-label study aimed to investigate the prevalence of spontaneous echo contrast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. Read More

View Article and Full-Text PDF

Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study.

BMJ Open 2021 05 31;11(5):e048839. Epub 2021 May 31.

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Objective: The study aimed to examine the association between socioeconomic factors (SEFs) and oral anticoagulation (OAC) therapy and whether it was influenced by changing guidelines. We hypothesised that inequities in initiation of OAC reduced over time as more detailed and explicit clinical guidelines were issued.

Design: Register-based observational study. Read More

View Article and Full-Text PDF

Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India.

Indian J Med Microbiol 2021 May 26. Epub 2021 May 26.

Department of Medicine, SP Medical College, Bikaner, Rajasthan, India.

Coronavirus disease 2019 (COVID-19), may present with a myriad of clinical manifestations and complications. Patients with COVID-19 are at increased risk of pulmonary thromboembolism, acute cardiac injury, arrhythmias, acute stroke, and secondary infections. Mucormycosis is a catastrophic fungal infection characterized by vascular invasion, thrombosis, and necrosis of tissues. Read More

View Article and Full-Text PDF

Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey.

Europace 2021 May;23(5):806-814

Serbia School of Medicine, University of Belgrade, Belgrade, Serbia.

The aim of this survey is to provide a snapshot of current practice regarding antithrombotic therapy (ATT) in patients with atrial fibrillation (AF) comorbid with intracerebral haemorrhage (ICH). An online survey was distributed to members of the European Heart Rhythm Association. A total of 163 clinicians responded, mostly cardiologists or electrophysiologists (87. Read More

View Article and Full-Text PDF

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.

Cardiovasc Diabetol 2021 05 7;20(1):100. Epub 2021 May 7.

Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Room 1929B/K1931, Block K, Hong Kong, China.

Background: Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regarding the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the risk of developing arrhythmias. This study aims to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF, DM, or CKD. Read More

View Article and Full-Text PDF

Five Hours of Resuscitation With 150 Electrical Shocks and Complete Recovery.

Cureus 2021 Apr 2;13(4):e14255. Epub 2021 Apr 2.

Cardiology, Carmel Medical Center, Haifa, ISR.

Background: Myocardial ischemia may lead to lethal arrhythmias. Treatment of these arrhythmias without addressing the cause of ischemia may be futile. The length of resuscitation is an important parameter for determining when to stop resuscitation but with shockable rhythms and reversible cause of the cardiac arrest, the decision to terminate resuscitation is complex. Read More

View Article and Full-Text PDF

Two Limitations of Subcutaneous Implantable Cardioverter Defibrillator in the Same Patient Warranting Its Explant.

Am J Case Rep 2021 Apr 29;22:e928983. Epub 2021 Apr 29.

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

BACKGROUND A subcutaneous implantable cardioverter defibrillator (S-ICD) is preferred over a transvenous implantable cardioverter defibrillator (TV-ICD) in selected cases owing to a lower rate of lead-related complications such as infections and venous thrombosis. However, the S-ICD has its own limitations, including inappropriate shocks due to oversensed events, and the inability to treat ventricular tachycardia (VT) below a heart rate of 170 beats per minutes (bpm). We present a patient case which showed manifestations of both of these limitations, warranting explant of the device. Read More

View Article and Full-Text PDF

Outcomes of COVID-19 Complications and their Possibilities as Potential Triggers of Stroke.

J Stroke Cerebrovasc Dis 2021 Jul 8;30(7):105805. Epub 2021 Apr 8.

Department of Neurology, University of Central Florida - HCA Consortium Neurology, Orlando, Florida, USA.

Introduction: There is limited literature on coronavirus disease 2019 (COVID -19) complications such as thromboembolism, cardiac complications etc. as possible trigger for stroke. Hence, we aim to evaluate the prevalence and outcomes of COVID-19 related cardiovascular complications and secondary infection and their possibility as potential triggers for the stroke. Read More

View Article and Full-Text PDF

Particulate Matter-Induced Cardiovascular Dysfunction: A Mechanistic Insight.

Cardiovasc Toxicol 2021 Jul 22;21(7):505-516. Epub 2021 Apr 22.

Integrated Genomics, Cellular, Developmental, and Biotechnology Laboratory (IGCDBL), University of Agriculture, Faisalabad, Punjab, 38000, Pakistan.

Air pollution and particulate matter (PM) are significant factors for adverse health effects most prominently cardiovascular disease (CVD). PM is produced from various sources, which include both natural and anthropogenic. It is composed of biological components, organic compounds, minerals, and metals, which are responsible for inducing inflammation and adverse health effects. Read More

View Article and Full-Text PDF

The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.

Cardiovasc Drugs Ther 2021 Apr 13. Epub 2021 Apr 13.

Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, 266100, Shandong, China.

Aim: In recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and further large-scale clinical trials and experimental studies are required to confirm the benefit of administering cardioprotective agents to patients treated with targeted therapies. Read More

View Article and Full-Text PDF

Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis.

Medicine (Baltimore) 2021 Apr;100(15):e25546

Institute of Cardiovascular Diseases, Jingzhou Central Hospital, Jingzhou Clinical Medical College, Yangtze University, Jingzhou, Hubei, PR China.

Background: In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI).

Methods: Medical Literature Analysis and Retrieval System Online (MEDLINE), http://www.ClinicalTrials. Read More

View Article and Full-Text PDF

Type 1 Acute Aortic Dissection in the Early Period After COVID-19 Infection.

Cureus 2021 Mar 7;13(3):e13751. Epub 2021 Mar 7.

Cardiovascular Surgery, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, TUR.

The coronavirus disease 2019 (COVID-19) pandemic has resulted in over 105 million confirmed cases and over 2.3 million deaths globally as of February 3, 2021. Cardiovascular problems due to COVID-19 infection include acute coronary syndrome (due to coronary occlusion, thrombosis), myocardial damage without coronary artery disease, arrhythmias, heart failure, pericardial effusion, and thromboembolic events. Read More

View Article and Full-Text PDF

Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.

Glob Heart 2021 02 12;16(1):14. Epub 2021 Feb 12.

Servicios y Tecnología Cardiovascular de Guatemala S.A, GT.

Background: Infection caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) exhibits a strong infectivity but less virulence compared to severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). In terms of cardiovascular morbidity, susceptible population include elderly and patients with certain cardiovascular conditions. This infection has been associated with cardiac injury, cardiovascular complications and higher mortality. Read More

View Article and Full-Text PDF
February 2021

Cardiovascular manifestations of COVID-19: An evidence-based narrative review.

Indian J Med Res 2021 Jan & Feb;153(1 & 2):7-16

Department of Cardiology, Advanced Cardiac Centre, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

The recent outbreak of coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization on March 11, 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, primarily involves the respiratory system with viral pneumonia as a predominant manifestation. In addition, SARS-CoV-2 has various cardiovascular manifestations which increase morbidity and mortality in COVID-19. Read More

View Article and Full-Text PDF

Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study.

Adv Ther 2021 05 27;38(5):2391-2405. Epub 2021 Mar 27.

Department of Cardiology, Memorial Ankara Hospital, Ankara, Turkey.

Introduction: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) aims to determine real-life treatment patterns and clinical outcomes of patients with newly diagnosed non-valvular atrial fibrillation (AF) and at least one investigator-determined risk factor for stroke. The registry includes a wide array of baseline characteristics and has a particular focus on: (1) bleeding and thromboembolic events; (2) international normalized ratio fluctuations; and (3) therapy compliance and persistence patterns.

Methods: Evolution in baseline treatment for patients enrolled in sequential cohorts showed an increase in prescribing of novel oral anticoagulants over time. Read More

View Article and Full-Text PDF

Challenges of left atrial appendage closure device and anticoagulation in a patient with immune thrombocytopenia (ITP).

BMJ Case Rep 2021 Mar 25;14(3). Epub 2021 Mar 25.

Department of Cardiology, Wayne State University, Detroit, Michigan, USA.

Among patients with atrial fibrillation (AF) who have high risk of bleeding secondary to haematologic disorders, left atrial appendage (LAA) occlusion therapy has been shown to be an excellent alternative to long-term use of oral anticoagulation for thromboembolic stroke prevention. However, there remains a major concern of device-associated thrombosis post-procedure, that can lead to life-threatening embolic events. To this date, there is no systematic guideline for the selection and management of patients with haematological disorders with LAA occlusion therapy, especially in those with platelet disorders such as immune thrombocytopenia (ITP). Read More

View Article and Full-Text PDF

The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.

Medicine (Baltimore) 2021 Mar;100(11):e25216

Department of Orthopedic Surgery, Ewha Womans University, College of Medicine, Seoul, Korea.

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used for stroke prevention in atrial fibrillation (AF) and the treatment and prevention of venous thromboembolism. There is an issue with safety, especially in clinically relevant bleeding. We performed a network meta-analysis to evaluate the risk of major gastrointestinal (GI) bleeding associated with NOACs. Read More

View Article and Full-Text PDF

Clinical outcomes following rhythm control for atrial fibrillation: is early better?

Expert Rev Cardiovasc Ther 2021 Apr 13;19(4):277-287. Epub 2021 Apr 13.

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.

: An integral aspect of atrial fibrillation (AF) management involves better symptom control, incorporating a rate control, rhythm control, or a combination strategy. The 2020 ESC Guidelines suggest that rhythm control strategy should be recommended for symptomatic patients, to mitigate their symptoms and improve the quality of life. However, adequately powered randomized control trials and prospective 'real-world' registries are needed to fully assess the impact of early rhythm control strategies on clinical outcomes in patients with AF. Read More

View Article and Full-Text PDF

Atrial fibrillation and vascular disease: Coronary artery disease and/or peripheral artery disease?

Arch Cardiovasc Dis 2021 03 9;114(3):173-175. Epub 2021 Mar 9.

Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, L14 3PE Liverpool, UK; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, 9220 Aalborg, Denmark. Electronic address:

View Article and Full-Text PDF

Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation.

Am J Cardiol 2021 04;144 Suppl 1:S32-S39

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

In patients with atrial fibrillation who undergo percutaneous coronary intervention (PCI), both anticoagulation and dual antiplatelet therapy (aspirin plus a P2Y inhibitor) are indicated. However, this "triple" antithrombotic therapy is associated with high rates of bleeding. Finding the right balance of reducing ischemic risk and protecting coronary stents from restenosis while not increasing bleeding risk is difficult. Read More

View Article and Full-Text PDF

Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants.

Int J Cardiol 2021 06 8;333:162-166. Epub 2021 Mar 8.

Department of Medical Science and Public Health, University of Cagliari, Italy.

Background: Patient's adherence to oral anticoagulant therapy is essential to prevent and treat thrombotic events.

Methods: To assess the patients' adherence Morisky Medication Adherence Scale 8-items was used. The target population included 785 consecutive outpatients, of whom 384 were on Vitamin K Antagonists and 401 on Direct Oral Anticoagulants. Read More

View Article and Full-Text PDF

COVID-19 and its cardiovascular effects: a systematic review of prevalence studies.

Cochrane Database Syst Rev 2021 03 11;3:CD013879. Epub 2021 Mar 11.

Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, UK.

Background: A small minority of people with coronavirus disease 2019 (COVID-19) develop a severe illness, characterised by inflammation, microvascular damage and coagulopathy, potentially leading to myocardial injury, venous thromboembolism (VTE) and arterial occlusive events. People with risk factors for or pre-existing cardiovascular disease may be at greater risk.

Objectives: To assess the prevalence of pre-existing cardiovascular comorbidities associated with suspected or confirmed cases of COVID-19 in a variety of settings, including the community, care homes and hospitals. Read More

View Article and Full-Text PDF

Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate.

J Thromb Haemost 2021 05 28;19(5):1348-1363. Epub 2021 Mar 28.

Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.

Introduction: Vitamin K antagonists (VKA) and non-vitamin K oral antagonist anticoagulants (NOAC) are used in the clinic to reduce risk of thrombosis. However, they also exhibit vascular off-target effects. The aim of this study is to compare VKA and NOAC on atherosclerosis progression and calcification in an experimental setup. Read More

View Article and Full-Text PDF

Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review.

Clin Drug Investig 2021 Apr 7;41(4):353-369. Epub 2021 Mar 7.

Duquesne University School of Pharmacy, 600 Forbes Ave, Pittsburgh, PA, 15282, USA.

Background And Objective: Rivaroxaban and apixaban are direct oral anticoagulants increasing in popularity as convenient alternatives to warfarin. However, current guidelines recommend against use in patients with a BMI > 40 kg/m or bodyweight > 120 kg unless drug-specific levels are measured, which may not be feasible across all clinical practices. Accordingly, the objective of this study was to broadly examine literature evaluating the clinical outcomes of rivaroxaban and/or apixaban in patients with increased body mass. Read More

View Article and Full-Text PDF

Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.

J Thromb Thrombolysis 2021 Mar 4. Epub 2021 Mar 4.

Section of Pulmonary, Critical Care, and Sleep, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Limited information is available about use of direct oral anticoagulants (DOACs) in lung transplant recipients (LTRs). The purpose of this study is to describe the indications and use of long-term anticoagulation, including the safety and tolerability of DOACs, in LTRs. This was a single-center retrospective study. Read More

View Article and Full-Text PDF

Beyond CHA2DS2-VASc for Predicting the Risk of Thromboembolism and Stroke - Not That Simple!

Arq Bras Cardiol 2021 02;116(2):332-333

ePHealth Primary Care Solutions, São Paulo, SP - Brasil.

View Article and Full-Text PDF
February 2021

Short-term direct oral anticoagulation or dual antiplatelet therapy following left atrial appendage closure in patients with relative contraindications to chronic anticoagulation therapy.

Int J Cardiol 2021 06 27;333:77-82. Epub 2021 Feb 27.

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address:

Background: Biological data suggest that short-term anticoagulation would be more effective than dual antiplatelet therapy (DAPT) to reduce the thrombotic risk following left atrial appendage closure (LAAC). This study sought to assess the safety and efficacy of direct oral anticoagulation (DOAC) versus DAPT immediately post-LAAC.

Methods: Multicenter study including 592 consecutive patients with relative contraindication to chronic anticoagulation who underwent LAAC and received either DAPT or DOAC for 1-3 months. Read More

View Article and Full-Text PDF

The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Eur Heart J Cardiovasc Pharmacother 2021 Feb 26. Epub 2021 Feb 26.

William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. However, there is no common position taken by international cardiovascular societies to unite diverse availability, interpretation and application of such data, nor is there recognition of the challenges of variation in clinical practice between countries within Europe. Aside from the considerable barriers to implementing pharmacogenomic testing and the complexities of clinically actioning results, there are differences in the availability of resources and expertise internationally within Europe. Read More

View Article and Full-Text PDF
February 2021